Clazinus Veijer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Clazinus Veijer has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Julia Maria Bes
Affiliation Nivel, Netherlands Institute for Health Services Research, Utrecht, The Netherlands
2 shared publications - Lisa Aniek de Jong
Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications - Maarten Jacobus Postma
Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 AB Groningen, The Netherlands, The Netherlands
2 shared publications Alike W. Van Der Velden
Julius Center for Health Science and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publicationAntoinette D. I. Van Asselt
Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
1 shared publication- Antoinette D. I. van Asselt
Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in The European Journal of Health Economics
- p. 1-12
Consultations, (antibiotic) prescriptions, and productivity losses of patients with community-acquired respiratory tract infection: country-specific findings from the PRUDENCE trial
Objective: Recent estimates of the cost-of-illness of community-acquired acute respiratory tract infections (CA-ARTI) are scarce. The current study aimed to estimate country-specific prescriptions, consultations, and productivity loss of patients with CA-ARTI in primary care. Methods: Data were collected via baseline data and a patient diary alongside the PRUDENCE trial. This multinational clinical trial recruited patients visiting their general practitioner (GP) with CA-ARTI symptoms in ten countries. Data collected included the antibiotic class prescribed, consultations with healthcare providers, non-antibiotic medication prescribed for CA-ARTI, disease duration, and missed working hours. Hours of work missed due to the disease were multiplied by country-specific hourly labour cost to calculate productivity loss in terms of absenteeism. Results: Proportions of CA-ARTI patients receiving an antibiotic prescription ranged from 37.2% in Germany to 68.2% in Ireland. Broad-spectrum penicillin was the most frequently prescribed class in Belgium, Germany, and Ireland (> 40%), whereas macrolides were most frequently prescribed in Georgia, Greece, and Hungary (> 36%). On average, approximately 50% of patients reported having a follow-up consultation with their GP within two weeks of the initial appointment. On average, work missed due to CA-ARTI was 15.4 h among employed patients, resulting in an average productivity loss of €358 per patient, and ranged from €1260 in Germany to €24 in Georgia. Conclusions: Antibiotic prescriptions, healthcare use, and missed work hours for CA-ARTI were substantially different across participating countries. This study adds valuable information on the generalizability of health economic evidence regarding CA-ARTI between countries and indicates the relevance to collect country-specific data and perform country-specific health economic analyses.
- 30 September 2026
- Published by Springer Nature in The European Journal of Health Economics
- p. 1-12
Open AccessConsultations, (antibiotic) prescriptions, and productivity losses of patients with community-acquired respiratory tract infection: country-specific findings from the PRUDENCE trial
Objective: Recent estimates of the cost-of-illness of community-acquired acute respiratory tract infections (CA-ARTI) are scarce. The current study aimed to estimate country-specific prescriptions, consultations, and productivity loss of patients with CA-ARTI in primary care. Methods: Data were collected via baseline data and a patient diary alongside the PRUDENCE trial. This multinational clinical trial recruited patients visiting their general practitioner (GP) with CA-ARTI symptoms in ten countries. Data collected included the antibiotic class prescribed, consultations with healthcare providers, non-antibiotic medication prescribed for CA-ARTI, disease duration, and missed working hours. Hours of work missed due to the disease were multiplied by country-specific hourly labour cost to calculate productivity loss in terms of absenteeism. Results: Proportions of CA-ARTI patients receiving an antibiotic prescription ranged from 37.2% in Germany to 68.2% in Ireland. Broad-spectrum penicillin was the most frequently prescribed class in Belgium, Germany, and Ireland (> 40%), whereas macrolides were most frequently prescribed in Georgia, Greece, and Hungary (> 36%). On average, approximately 50% of patients reported having a follow-up consultation with their GP within two weeks of the initial appointment. On average, work missed due to CA-ARTI was 15.4 h among employed patients, resulting in an average productivity loss of €358 per patient, and ranged from €1260 in Germany to €24 in Georgia. Conclusions: Antibiotic prescriptions, healthcare use, and missed work hours for CA-ARTI were substantially different across participating countries. This study adds valuable information on the generalizability of health economic evidence regarding CA-ARTI between countries and indicates the relevance to collect country-specific data and perform country-specific health economic analyses.
- Open Access
- 4 June 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 170, 108854
Healthcare resource use and costs under pandemic circumstances in The Netherlands: Results from the lifelines COVID-19 cohort
- 4 June 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 170, 108854
Open AccessHealthcare resource use and costs under pandemic circumstances in The Netherlands: Results from the lifelines COVID-19 cohort
- Open Access
- 8 September 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002057
Epidemiological trends and economic burden of genital warts in Dutch primary care
Background : This study aims to describe the epidemiological trends and estimate the economic burden of genital warts (GW) in Dutch primary care. Methods: A retrospective, non-interventional, multiyear study (2011–2021) was performed using data from the Nivel Primary Care Database. Changes in incidence by age group, sex and level of urbanisation of individuals with GW and associated healthcare resource use (general practitioner consultations, prescribed medication and referrals) were estimated over the 11-year period. Total annual healthcare costs and cost per incident case were estimated via a bottom-up gross costing approach. Results : Between 2011 and 2021, GW incidence increased, which was especially seen in men (from 2.0 to 3.5 per 1000 inhabitants) and to a lesser extent in women (from 1.9 to 2.1 per 1000 inhabitants). GW incidence was most common in age group 20–29 years (men: 43.6%; women: 50.7%) and highly urbanised areas. Medication was prescribed in 61.4% of GW cases, and 5.4% of patients with GW were referred to secondary care. Total costs in Dutch primary care increased by 108% from €2.3 million in 2011 to €4.9 million in 2021. The cost per incident case also showed an increasing trend from €72 in 2011 to €99 in 2021. Referrals to secondary care resulted in a 14%–30% increase in total costs. Conclusions: This study provides novel insights into recent epidemiological trends of GW and its associated costs in Dutch primary care. The incidence of GW increased particularly among men, and the total annual costs of GW in primary care doubled between 2011 and 2021.
- 8 September 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002057
Open AccessEpidemiological trends and economic burden of genital warts in Dutch primary care
Background : This study aims to describe the epidemiological trends and estimate the economic burden of genital warts (GW) in Dutch primary care. Methods: A retrospective, non-interventional, multiyear study (2011–2021) was performed using data from the Nivel Primary Care Database. Changes in incidence by age group, sex and level of urbanisation of individuals with GW and associated healthcare resource use (general practitioner consultations, prescribed medication and referrals) were estimated over the 11-year period. Total annual healthcare costs and cost per incident case were estimated via a bottom-up gross costing approach. Results : Between 2011 and 2021, GW incidence increased, which was especially seen in men (from 2.0 to 3.5 per 1000 inhabitants) and to a lesser extent in women (from 1.9 to 2.1 per 1000 inhabitants). GW incidence was most common in age group 20–29 years (men: 43.6%; women: 50.7%) and highly urbanised areas. Medication was prescribed in 61.4% of GW cases, and 5.4% of patients with GW were referred to secondary care. Total costs in Dutch primary care increased by 108% from €2.3 million in 2011 to €4.9 million in 2021. The cost per incident case also showed an increasing trend from €72 in 2011 to €99 in 2021. Referrals to secondary care resulted in a 14%–30% increase in total costs. Conclusions: This study provides novel insights into recent epidemiological trends of GW and its associated costs in Dutch primary care. The incidence of GW increased particularly among men, and the total annual costs of GW in primary care doubled between 2011 and 2021.
- Open Access
Epidemiological Trends and Economic Burden of Genital Warts in Dutch Primary Care
Background: This study aims to describe the epidemiological trends and estimate the economic burden of genital warts (GW) in Dutch primary care. Methods: A retrospective, non-interventional, multiyear study (2011-2021) was performed using data from the Nivel Primary Care Database. Changes in incidence by age group, sex, and level of urbanisation of individuals with GW and associated healthcare resource use (general practitioner consultations, prescribed medication, and referrals) were estimated over the 11-year period. Total annual healthcare costs and cost per incident case were estimated via a bottom-up gross costing approach. Results: Between 2011 and 2021, GW incidence increased, which was especially seen in men (from 2.0 to 3.5 per 1 000 inhabitants) and to a lesser extent in women (from 1.9 to 2.1 per 1 000 inhabitants). GW incidence was most common in age group 20-29 years (men: 43.6%; women: 50.7%) and highly urbanised areas. Medication was prescribed in 61.4% of GW cases, and 5.4% of GW patients were referred to secondary care. Total costs in Dutch primary care increased by 108% from EUR 2.3 million in 2011 to EUR 4.9 million in 2021. The cost per incident case also showed an increasing trend from EUR 72 in 2011 to EUR 99 in 2021. Referrals to secondary care resulted in a 14-30% increase of total costs. Conclusions: This study provides novel insights into recent epidemiological trends of GW and its associated costs in Dutch primary care. Incidence especially increased among men and total annual costs of GW in primary care doubled between 2011 and 2021.
Open AccessEpidemiological Trends and Economic Burden of Genital Warts in Dutch Primary Care
Background: This study aims to describe the epidemiological trends and estimate the economic burden of genital warts (GW) in Dutch primary care. Methods: A retrospective, non-interventional, multiyear study (2011-2021) was performed using data from the Nivel Primary Care Database. Changes in incidence by age group, sex, and level of urbanisation of individuals with GW and associated healthcare resource use (general practitioner consultations, prescribed medication, and referrals) were estimated over the 11-year period. Total annual healthcare costs and cost per incident case were estimated via a bottom-up gross costing approach. Results: Between 2011 and 2021, GW incidence increased, which was especially seen in men (from 2.0 to 3.5 per 1 000 inhabitants) and to a lesser extent in women (from 1.9 to 2.1 per 1 000 inhabitants). GW incidence was most common in age group 20-29 years (men: 43.6%; women: 50.7%) and highly urbanised areas. Medication was prescribed in 61.4% of GW cases, and 5.4% of GW patients were referred to secondary care. Total costs in Dutch primary care increased by 108% from EUR 2.3 million in 2011 to EUR 4.9 million in 2021. The cost per incident case also showed an increasing trend from EUR 72 in 2011 to EUR 99 in 2021. Referrals to secondary care resulted in a 14-30% increase of total costs. Conclusions: This study provides novel insights into recent epidemiological trends of GW and its associated costs in Dutch primary care. Incidence especially increased among men and total annual costs of GW in primary care doubled between 2011 and 2021.
- Open Access
- 10 May 2024
- Published by Springer Nature in PharmacoEconomics
- Vol. 42 (6) , 633-647
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review
Background Following clinical research of potential coronavirus disease 2019 (COVID-19) treatments, numerous decision–analytic models have been developed. Due to pandemic circumstances, clinical evidence was limited and modelling choices were made under great uncertainty. This study aimed to analyse key methodological characteristics of model-based economic evaluations of COVID-19 drug treatments, and specifically focused on modelling choices which pertain to disease severity levels during hospitalisation, model structure, sources of effectiveness and quality of life and long-term sequelae. Methods We conducted a systematic literature review and searched key databases (including MEDLINE, EMBASE, Web of Science, Scopus) for original articles on model-based full economic evaluations of COVID-19 drug treatments. Studies focussing on vaccines, diagnostic techniques and non-pharmaceutical interventions were excluded. The search was last rerun on 22 July 2023. Results were narratively synthesised in tabular form. Several aspects were categorised into rubrics to enable comparison across studies. Results Of the 1047 records identified, 27 were included, and 23 studies (85.2%) differentiated patients by disease severity in the hospitalisation phase. Patients were differentiated by type of respiratory support, level of care management, a combination of both or symptoms. A Markov model was applied in 16 studies (59.3%), whether or not preceded by a decision tree or an epidemiological model. Most cost–utility analyses lacked the incorporation of COVID-19-specific health utility values. Of ten studies with a lifetime horizon, seven adjusted general population estimates to account for long-term sequelae (i.e. mortality, quality of life and costs), lasting for 1 year, 5 years, or a patient’s lifetime. The most often reported parameter influencing the outcome of the analysis was related to treatment effectiveness. Conclusion The results illustrate the variety in modelling approaches of COVID-19 drug treatments and address the need for a more standardized approach in model-based economic evaluations of infectious diseases such as COVID-19. Trial Registry Protocol registered in PROSPERO under CRD42023407646.
- 10 May 2024
- Published by Springer Nature in PharmacoEconomics
- Vol. 42 (6) , 633-647
Open AccessLessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review
Background Following clinical research of potential coronavirus disease 2019 (COVID-19) treatments, numerous decision–analytic models have been developed. Due to pandemic circumstances, clinical evidence was limited and modelling choices were made under great uncertainty. This study aimed to analyse key methodological characteristics of model-based economic evaluations of COVID-19 drug treatments, and specifically focused on modelling choices which pertain to disease severity levels during hospitalisation, model structure, sources of effectiveness and quality of life and long-term sequelae. Methods We conducted a systematic literature review and searched key databases (including MEDLINE, EMBASE, Web of Science, Scopus) for original articles on model-based full economic evaluations of COVID-19 drug treatments. Studies focussing on vaccines, diagnostic techniques and non-pharmaceutical interventions were excluded. The search was last rerun on 22 July 2023. Results were narratively synthesised in tabular form. Several aspects were categorised into rubrics to enable comparison across studies. Results Of the 1047 records identified, 27 were included, and 23 studies (85.2%) differentiated patients by disease severity in the hospitalisation phase. Patients were differentiated by type of respiratory support, level of care management, a combination of both or symptoms. A Markov model was applied in 16 studies (59.3%), whether or not preceded by a decision tree or an epidemiological model. Most cost–utility analyses lacked the incorporation of COVID-19-specific health utility values. Of ten studies with a lifetime horizon, seven adjusted general population estimates to account for long-term sequelae (i.e. mortality, quality of life and costs), lasting for 1 year, 5 years, or a patient’s lifetime. The most often reported parameter influencing the outcome of the analysis was related to treatment effectiveness. Conclusion The results illustrate the variety in modelling approaches of COVID-19 drug treatments and address the need for a more standardized approach in model-based economic evaluations of infectious diseases such as COVID-19. Trial Registry Protocol registered in PROSPERO under CRD42023407646.